ABPI Proposes ‘World-First’ Investment Facility As Part Of New Pricing Deal
A ‘Medicines Equity Partnership’ Is Also On The Cards
Executive Summary
The Association of the British Pharmaceutical Industry says a new type of investment facility funded by the pharmaceutical industry could form part of a new pricing agreement for branded medicines, and would be a “genuine Brexit dividend.”
You may also be interested in...
ABPI Chooses Pfizer’s Susan Rienow As New President
Susan Rienow, UK country president of Pfizer, is to formally replace Pinder Sahota, UK manager of Novo Nordisk, as president of the UK pharmaceutical industry trade group, the ABPI.
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.